Video above: FDA votes to authorize more COVID-19 boosters, mix-and-matching doses in some casesA booster dose of the Pfizer/BioNTech coronavirus vaccine was found to have a high efficacy — 95.6% — ...

NEW YORK - Pfizer and its German partner BioNTech on Thursday shared results from the Phase 3 trial of their COVID-19 vaccine booster, saying the additional third dose showed 95.6% efficacy against ...

Pfizer Inc. and BioNTech SE have announced that their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior ...

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...

COVID-19 vaccine recommendations could be changing, according to the U.S. Food and Drug Administration. FDA leaders said on May 20 that clinical trials will be required to approve annual COVID-19 ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (PFE) (NYSE: PFE, “Pfizer”) and BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) ...